TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Inventory
Raw materials, work in progress, and finished goods held for sale.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Inventory · Q1 FY2026 · quarter ended Mar 2026
Inventory falls 9.2% from a year ago
Inventory stood at $3.78M at the end of Q1 FY2026, down 9.2% from a year earlier and up 22.8% from the prior quarter. Over 3 fiscal years it compounded at +27.9% a year.
Context
- Inventory amounted to 5.3% of total assets at the end of Q1 FY2026, down 9.2 pp from a year earlier.
- Inventory increased in 2 of the last 3 fiscal years.
What to watch
Whether inventory keeps falling in the next quarterly balance sheet after a -9.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 3.08M USD
- Year-over-year change
- -24.0%
- 4-year CAGR
- +24.2%
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.08M | -24.0% |
| FY2024 | 2024-12-31 | 4.05M | +59.1% |
| FY2023 | 2023-12-31 | 2.55M | +73.0% |
| FY2022 | 2022-12-31 | 1.47M | +13.9% |
| FY2021 | 2021-12-31 | 1.29M | — |
Inventory vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's Mar 2026 inventory of $3.78M is the 7th highest of the 11 companies compared; the peer median is $6.17M.
- Its year-over-year change of -9.2% is the 8th highest of 9, against a peer median of +41.8%.
- Inventory amounts to 5.3% of total assets for TLSI, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $23.1M | +50.7% | +22.4% | 34.9% | |
| Mar 2026 | $18.19M | +54.0% | -6.2% | 21.0% | |
| Mar 2026 | $14.2M | +114.8% | +15.9% | 8.1% | |
| Mar 2026 | $9.03M | +32.9% | +12.4% | 12.3% | |
| Mar 2026 | $7.63M | -7.8% | -4.2% | 3.9% | |
| Mar 2026 | $4.72M | +15.9% | -21.4% | 3.8% | |
| Mar 2026 | $3.78M | -9.2% | +27.9% | 5.3% | |
| Dec 2025 | $3.07M | +105.6% | +8.3% | 1.9% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $122K | -66.5% | +27.4% | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TLSI) | $6.17M | +41.8% | +10.4% | 3.8% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.3M | 9.41M | 11.78M | 8.53M | 20.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.36M | 1.56M | 3.55M | 5.09M | 6.56M |
| Inventory | 1.29M | 1.47M | 2.55M | 4.05M | 3.08M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 35.13M | 17.21M | 20.86M | 20.67M | 32.24M |
| Property, Plant & Equipment (Net) | 1.8M | 3.61M | 3.27M | 2.88M | 2.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 794K | 802K | 0 | 0 | 0 |
| Long-term Investments | 0 | 250K | 0 | 350K | 400K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115K | 117K | 466K | 73K | 18K |
| Total Non-current Assets | 2.71M | 4.78M | 3.74M | 3.3M | 3.09M |
| Total Assets | 37.84M | 22M | 24.6M | 23.97M | 35.33M |
| Account Payables | 1.3M | 4.95M | 3.39M | 2.27M | 3M |
| Short-term Debt | 0 | 370K | 0 | 0 | 167K |
| Tax Payables | 0 | 0 | 0 | 34K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 104K | 23.57M | 420K | 383K | 8.23M |
| Total Current Liabilities | 6.37M | 32.36M | 14.69M | 10.23M | 11.5M |
| Long-term Debt | 0 | 0 | 0 | 22.08M | 34.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 561K | 369K | 35.73M | 16.22M | 23.42M |
| Total Non-current Liabilities | 561K | 1.96M | 36.98M | 39.64M | 57.69M |
| Total Liabilities | 6.93M | 34.32M | 51.66M | 49.87M | 69.19M |
| Common Stock | 11K | 0 | 2K | 3K | 4K |
| Retained Earnings | (136.34M) | (186.36M) | (249.5M) | (279.55M) | (330.58M) |
| Accumulated OCI | 0 | 0 | (0) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.9M | (12.32M) | (27.07M) | (25.89M) | (33.86M) |
| Total Debt | 0 | 1.96M | 1.6M | 23.63M | 34.44M |
| Net Debt | (30.3M) | (7.45M) | (10.18M) | 15.1M | 14M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.